Prognostic signifi cance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer

Oncology

Volumn 67, Issue 3-4, 2004, Pages 300-309

  Sharma, Rinu ^a   Chattopadhyay, Tushar Kant ^a   Mathur, Meera ^a   Ralhan, Ranju ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Esophageal cancer; Invasion; ST 2; ST 3; TIMP 1; TIMP 2

Indexed keywords

PROTEIN P53; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; METALLOPROTEINASE; TUMOR MARKER;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; ANALYSIS OF VARIANCE; CHEMISTRY; DISEASE COURSE; ESOPHAGUS TUMOR; LYMPH NODE METASTASIS; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL;

ADULT; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 11; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 9244237642     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081331     Document Type: Article

References (59)

1. Blasi F, Stoppelli MP: Proteases and cancer invasion: From belief to certainty. Biochim Biophys Acta 1998; 1423:R35-R44.
2. Moel A, Giljes C, Bajou K: Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17: 221-280.
3. Curran S, Murray GI: Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36: 1621-1630.
4. Wyke JA: Overview - Burgeoning promise in metastasis research. Eur J Cancer 2000; 36:1589-1594.
5. Murphy G, Cockett MI, Ward RV, Docherty AJ: Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: A quantitative comparison of activities of 95 kDa and 75 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277: 277-279.
6. Muller D, Breathnach R, Engelmann A: Expression of collagenase-related metalloproteinase gene in human lung or head and neck tumors. Int J Cancer 1991; 48: 550-556.
7. Boddey B, Bodey Bela JR, Siegel S: Immunohistochemical detection of MMP-3 and MMP-10 expression in hepatocellular carcinomas. Anticancer Res 2000; 20: 4585-4590.
8. Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK, Ralhan R: Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: Potential clinical implications. Cancer Detect Prev 2002; 26: 222-228.
9. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 20: 699-704.
10. Murphy G, Segain JP, O'Shea M, Cockett M, Ioannou C, Lefebvre O, Chambon P, Basset P: The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J Biol Chem 1993;268: 15435-15441.
11. Pei D, Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995; 375: 244-247.
12. Lefebvre O, Wolf C, Limacher JM, Hutin P, Wendling C, LeMeur M, Basset P, Rio MC: The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis . J Cell Biol 1992; 119: 997-1002.
13. Lefebvre O, Regnier C, Chenard MP, Wendling C, Chambon P, Basset P, Rio MC: Developmental expression of mouse stromelysin-3 mRNA. Development 1995; 21: 947-955.
14. Okada A, Tomasetto C, Lutz Y, Bellocq JP, Rio MC, Basset P: Expression of matrix metalloproteinases during rat skin wound healing: Evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997; 137: 67-77.
15. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautes-Fridman C, Basset P, Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 2001; 61: 2189-2193.
16. Rio MC, Lefebvre O, Santavicca M, Noel A, Chenard MP, Anglard P, Byrne JA, Okada A, Regnier CH, Masson R, Bellocq JP, Basset P: Stromelysin-3 in the biology of the normal and neoplastic mammary gland. J Mammary Gland Biol Neoplasia 1996; 2: 231-240.
17. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, Basset P, Rio MC: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140: 1535-1541.
18. Basset P, Bellocq JP, Lefebvre O, Noel A, Chenard MP, Wolf C, Anglard P, Rio MC: Stromelysin-3: A paradigm for stroma-derived factors implicated in carcinoma progression. Crit Rev Oncol Hematol 1997; 26: 43-53.
19. Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996; 69: 448-451.
20. Ahmad A, Hanby A, Dublin E, Poulsom R, Smith P, Barnes D, Rubens R, Anglard P, Hart I: Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 1998; 152: 721-728.
21. Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA: Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary . broblasts. Cancer Res 1995; 55:4120-4126.
22. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995; 64: 70-75.
23. Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H, Hofler H: Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch 2000; 437: 618-624.
24. Gomez DE, Alonso DF, Yoshiji H: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
25. Sato H, Kida Y, Mai M: Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992; 7: 77-83.
26. Miyagi E, Yasumitsu H, Hirahara F: Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Jpn J Cancer Res 1995; 86:568-576.
27. Belloc C, Lu H, Soria C: The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995;60: 413-417.
28. Azuma M, Tamatani T, Fukui K: Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells. Int J Cancer 1993; 54:669-676.
29. DeClerck YA, Imren S: Protease inhibitors: Role and potential therapeutic use in human cancer. Eur J Cancer 1994; 30A:2170-2180.
30. Imren S, Kohn DB, Shimada H: Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891-2895.
31. Noel A, Gilles C, Bajou K: Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17: 221-239.
32. Hayakawa T, Yamashita K, Tanzawa K: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298: 29-32.
33. Guedez L, Stetler-Stevenson WG, Wolff L: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998; 102: 2002-2010.
34. Li G, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59: 6267-6275.
35. Jiang Y, Wang M, Celiker MY: Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001; 61: 2365-2370.
36. Guedez L, McMarlin AJ, Kingma DW: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001; 158: 1207-1215.
37. Landis SH, Murray T, Bolden S: Cancer statistics. CA Cancer J Clin 1999; 49: 8-31.
38. Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 1995; 55: 1856-1862.
39. Shimada Y, Imamura M, Watanabe G: Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999; 80: 1281-1288.
40. Sobin LH, Fleming ID: TNM Classi. cation of Malignant Tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80:1803-1804.
41. Mathew R, Arora S, Khanna R: Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer 2002; 38: 832-841.
42. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E: Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis. Clin Cancer Res 1998; 4: 1375-1382.
43. Uria JA, Otin CL: Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000; 60: 4745-4751.
44. Sternlicht MD, Lotcher A, Sympson CJ: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98:137-146.
45. Yu Q, Stamenkovic I: Cell surface localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000; 15: 163-176.
46. Stetler-Stevenson EG: Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999; 103:1237-1241.
47. Galateau-Salle FB, Luna RE, Horiba K: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 2000; 31: 296-305.
48. Bian J, Sun Y: Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997; 17: 6330-6338.
49. Araya J, Maruyama M, Sassa K, Fujita T, Hayashi R, Matsui S, Kashii T, Yamashita N, Sugiyama E, Kobayashi M: Ionizing radiation enhances matrix metalloproteinase-2 production in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2001; 280:L30-L38.
50. Sun Y, Sun Y, Wenger L: p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem 1999;274: 11535-11540.
51. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, Howell DS, Cheung HS: Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000;275: 11327-11332.
52. Guedez L, McMarlin AJ, Kingma DW: Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001; 158: 1207-1215.
53. Luparello C, Avanzato G, Carella C: Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999; 54: 235-244.
54. Yoshiji H, Harris SR, Raso E: Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998; 75: 81-87.
55. Goss KJ, Brown PD, Matrisian LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 1998; 78: 629-635.
56. Hoegy SE, Oh HR, Corcoran ML: Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 2001; 276: 3203-3214.
57. Blavier L, Henriet P, Imren S: Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 1999; 878: 108-119.
58. McCarthy K, Maguire T, McGreal G: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999; 84: 44-48.
59. Noel A, Boulay A, Kebers F: Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000; 19: 1605-1612.